TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29929385
Drug: Testosterone replacement
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone replacement therapy (1000 mg long-acting undecanoate testosterone via intramuscular injection every 3 months)
Study: 15928719
Drug: Oral L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral L-arginine (3.0 t.i.d p.o. for 30 days)
Study: 15928719
Drug: Oral L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral L-arginine
Study: 10338173
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL 1.5% mepivacaine with proximal digital pressure
Study: 10338173
Drug: 40 mL
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL 1.5% mepivacaine without digital pressure
Study: 1752075
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly subcutaneous administration of recombinant human erythropoietin (rHuEPO) at a starting dose of 100 U/kg body wt/week
Study: 1752075
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly subcutaneous administration of recombinant human erythropoietin (rHuEPO) at a starting dose of 100 U/kg body wt/week
Study: 28911144
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (G1) - empiric two-pill/week dose increase followed by subsequent pill-per-week dose adjustments
Study: 28911144
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (G2) - ongoing adjustment based on current TSH level and LT4 dose
Study: 19678751
Drug: Prescription dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription dose NAPSO (550 mg twice daily)
Study: 19678751
Drug: OTC doses
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTC doses of NAPSO (220 mg two or three times daily)
Study: 19678751
Drug: EC‐ASA 81
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC‐ASA 81 mg once daily
Study: 1415367
Drug: 2.6% amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.6% amino acid solution
Study: 16173387
Drug: Carisolv treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carisolv treatment
Study: 12190173
Drug: Misoprostol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (400 microg, two doses)
Study: 6113351
Drug: Effective CNS
Normalized name: CN-105
DrugBank: CN-105 (DB18345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effective CNS treatment before symptoms arise
Study: 6113351
Drug: Prophylactic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic therapy
Study: 6113351
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy and better general management
Study: 29203503
Drug: Stimulation programme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulation programme administered by parents between 37 weeks' gestation and 6 months' corrected age
Study: 29203503
Drug: Stimulation programme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulation programme administered by parents
Study: 21739119
Drug: Trabectedin (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabectedin (1.3 mg/m²)
Study: 9893656
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (MA) 320 mg/day (two 160 mg tablets/day)
Study: 8017124
Drug: Dried preparation
Normalized name: peptone,dried
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dried preparation of bifidumbacterin administered for 4-6 days
Study: 8017124
Drug: Dried preparation
Normalized name: peptone,dried
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dried preparation of bifidumbacterin
Study: 2681838
Drug: Indomethacin suppository
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin suppository (50 to 100 mg)
Study: 27906800
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri DSM 17938 10⁸ CFU daily
Study: 24063578
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment including Lugol's iodine staining
Study: 24063578
Drug: Standard surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard surgical treatment arm
Study: 10518847
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension (BIS) at total daily doses of 0.25 mg, 0.5 mg, 1.0 mg, and 2.0 mg
Study: 1837606
Drug: Alternative group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative group (1/5 of the treatment group's exercise program per session)
Study: 1837606
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (completed training at least once a week for 1 year)
Study: 7019266
Drug: 0.1% stannous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% stannous fluoride (SnF2), rinsed twice daily for 5 days
Study: 7019266
Drug: 0.2% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% chlorhexidine digluconate, rinsed twice daily for 5 days after SnF2
Study: 15948743
Drug: BCG (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG (81 mg Connaught strain)
Study: 15948743
Drug: Epirubicin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (50 mg)
Study: 11837383
Drug: Moexipril 15
Normalized name: moexipril 15 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moexipril 15 mg single oral dose in fasting state
Study: 11837383
Drug: Moexipril 15
Normalized name: moexipril 15 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moexipril 15 mg single oral dose in postprandial state
Study: 11837383
Drug: Moexipril 15
Normalized name: moexipril 15 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moexipril 15 mg single oral dose
Study: 11837383
Drug: Moexipril 15
Normalized name: moexipril 15 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moexipril 15 mg once daily for 5 days
Study: 10445897
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group with access to case management and community care benefits (up to $699 per month)
Study: 8665543
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 5 mg selegeline
Study: 8665543
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 10 mg selegeline
Study: 1706014
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (enalapril 20 mg + sustained-release diltiazem 300 mg)
Study: 30610862
Drug: FMTv (Fecal
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMTv (Fecal Microbiota Transplantation after 4-10 days of vancomycin 125 mg 4 times daily)
Study: 30610862
Drug: fidaxomicin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: fidaxomicin (200 mg twice daily for 10 days)
Study: 30610862
Drug: vancomycin (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: vancomycin (125 mg 4 times daily for 10 days)
Study: 19819004
Drug: Modified killed-whole-cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified killed-whole-cell cholera vaccine
Study: 8968432
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of hydrochlorothiazide, atenolol, captopril, diltiazem‐SR, clonidine, and prazosin
Study: 1319735
Drug: L (80
Normalized name: ASFOTASE ALFA 100MG/ML INJ 0.8ML (80MG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L (80 mg/day lovastatin)
Study: 1319735
Drug: L +
Normalized name: Citracal + D
Approvals — FDA: no, EMA: no, PMDA: no
Description: L + GG (80 mg/day lovastatin + 20 g/day guar gum)
Study: 1319735
Drug: L +
Normalized name: Citracal + D
Approvals — FDA: no, EMA: no, PMDA: no
Description: L + C (80 mg/day lovastatin + 16 g/day cholestyramine)
Study: 30951267
Drug: Treating early,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treating early, intensively and to target (specific treatment details not provided)
Study: 30951267
Drug: Treatment type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment type (not specified)
Study: 28328346
Drug: Live, oral
Normalized name: typhoid vaccine, live, oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live, oral bovine rotavirus pentavalent vaccine (BRV-PV)
Study: 23515453
Drug: Org 43553
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 43553 (25-900 mg)
Study: 23515453
Drug: Org 43902
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 43902 (30-300 mg)
Study: 20980485
Drug: Serum concentrations
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum concentrations of 25(OH)D ≥ 30 ng/mL
Study: 8085125
Drug: 1% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% glucose solution
Study: 8085125
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no glucose solution)
Study: 1067480
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with 6 mercaptopurine (6 MP) and methotrexate (MTX)
Study: 1067480
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with 6 mercaptopurine (6 MP), methotrexate (MTX) and cyclophosphamide (Cyclo)
Study: 1067480
Drug: CNS prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNS prophylaxis with cranial radiation (2500 rad) and intrathecal administration of methotrexate (MTX) and prednisolone
Study: 1067480
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment including induction therapy with vincristine (VCR) and prednisone (Pred)
Study: 1067480
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment including maintenance therapy
Study: 28379861
Drug: Extended-Release Injectable
Normalized name: Exenatide for Extended-Release Injectable Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-Release Injectable Naltrexone (XR-NTX) 380 mg, 6 monthly doses
Study: 24460005
Drug: Jump 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jump 10 group (10 jumps, twice daily for 16 weeks)
Study: 24460005
Drug: Jump 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jump 20 group (20 jumps, twice daily for 16 weeks)
Study: 23411791
Drug: Whole body
Normalized name: MaxiVision Whole Body Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole body vibration training combined with conventional physical therapy training
Study: 23411791
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy training
Study: 6142208
Drug: Artificial surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial surfactant therapy (30 mg dipalmitoylphosphatidylcholine and 3 mg high-density lipoprotein in a 5 ml suspension)
Study: 6142208
Drug: Artificial surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial surfactant therapy
Study: 24661511
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (amoxicillin 40 mg/(kg·d), Tid; clarithromycin 15 mg/(kg·d), Bid; omeprazole 0.7-0.8 mg/(kg·d), Qd)
Study: 24661511
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy combined with Saccharomyces boulardii (250 mg, Bid)
Study: 23171757
Drug: Inactivated PCV2
Normalized name: poliovirus vaccine inactivated, type 1 (Mahoney)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated PCV2 vaccine
Study: 20601905
Drug: Probiotic and
Normalized name: Florastor Advanced Probiotic And Digestive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic and prebiotic fortified milk (1.9 x 10 colony-forming units of Bifidobacterium lactis HN019 and 2.4 g/day of prebiotic oligosaccharides)
Study: 15702140
Drug: TYR-free amino
Normalized name: Tyr
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TYR-free amino acid drink (74 g, lacking TYR and PHE)
Study: 12093460
Drug: 19.6 g
Normalized name: ALUMINUM CHLOROHYDRATE 19.6 g in 100 g TOPICAL STICK [Dove]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 19.6 g of arginine/d for 14 days (n = 6)
Study: 11225649
Drug: Niacin-bound chromium
Normalized name: chromium picolinate / niacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin-bound chromium 600 microg daily for 2 months
Study: 7586602
Drug: Calculated dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calculated dose group (131I dose based on thyroid gland type, accurate volume measurement, and 24-hour uptake determination)
Study: 7586602
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose group (fixed doses of 185, 370, or 555 MBq based on gland size assessment by palpation)
Study: 30004570
Drug: PFNA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PFNA treatment
Study: 18035199
Drug: Erdosteine 225
Normalized name: erdosteine
DrugBank: Erdosteine (DB05057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erdosteine 225 mg BID and chest physiotherapy
Study: 29553432
Drug: General anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anaesthesia (20% intravenous propofol for induction, atracurium for muscle relaxation, nitrous oxide and oxygen for maintenance)
Study: 29553432
Drug: Spinal anaesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anaesthesia (0.5% hyperbaric solution bupivacaine with 20 μg fentanyl intrathecally)
Study: 20175608
Drug: Person-centered therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Person-centered therapy
Study: 16304166
Drug: Azithromycin (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (oral and intravenous doses)
Study: 2802118
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion (3.93 mg/kg)
Study: 4404939
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g ampicillin daily
Study: 4404939
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g ampicillin daily
Study: 4404939
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g ampicillin daily + 20 mg prednisolone daily
Study: 4404939
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g ampicillin daily + 20 mg prednisolone daily
Study: 27158908
Drug: Benznidazole 5
Normalized name: Benznidazole 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benznidazole 5 mg/Kg/day for 60 days (n = 47)
Study: 27158908
Drug: Benznidazole 5
Normalized name: Benznidazole 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benznidazole 5 mg/Kg/day open-label (n = 16)
Study: 24069472
Drug: Benznidazole treatment
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benznidazole treatment
Study: 22429273
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive administered 30 minutes after exenatide
Study: 22429273
Drug: Repeated daily
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated daily oral contraceptive administration 30 minutes after exenatide
Study: 22429273
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive administered 1 hour before exenatide
Study: 21246844
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (Shenmen (HT 7), Baihui (CV 20), Hegu (LI 4), Taichong (LR 3))
Study: 21246844
Drug: Trazodone (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (oral administration for 4 weeks)
Study: 14598513
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of naltrexone and SSRI antidepressants
Study: 8309864
Drug: HMG-CoA reductase
Normalized name: HMG-CoA reductase
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMG-CoA reductase inhibitors and gemfibrozil (Lopid)
Study: 2453766
Drug: Birth control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Birth control vaccine (synthetic peptide antigen representing the aminoacid sequence 109‐145 of the C‐terminal region of the beta subunit of human chorionic gonadotropin)
Study: 22782995
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 10 ml/kg
Study: 22782995
Drug: Dopamine 2.5-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine 2.5-5 mcg/kg per min
Study: 16904519
Drug: AF+C (Accelerated
Approvals — FDA: no, EMA: no, PMDA: no
Description: AF+C (Accelerated Fractionation with Concurrent Chemotherapy)
Study: 16904519
Drug: CF+C (Conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: CF+C (Conventional Fractionation with Concurrent Chemotherapy)
Study: 16904519
Drug: Both CRT
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both CRT arms (Concurrent Chemoradiotherapy)
Study: 8873700
Drug: Bromocriptine mesylate
Normalized name: Bromocriptine Mesylate
DrugBank: Bromocriptine (DB01200)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bromocriptine mesylate (12.5 mg/day for 28 days)
Study: 1676367
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fenoldopam and enalapril
Study: 26426577
Drug: ropivacaine 0.1%
Normalized name: ROPivacaine 0.1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine 0.1% and clonidine 1.5 μg ml⁻¹ (RC1.5 group; n = 65)
Study: 26426577
Drug: ropivacaine 0.1%
Normalized name: ROPivacaine 0.1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine 0.1% and clonidine 3 μg ml⁻¹ (RC3 group; n = 65)
Study: 26426577
Drug: ropivacaine 0.1%
Normalized name: ROPivacaine 0.1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine 0.1% and sufentanil 0.25 μg ml⁻¹ (RS group; n = 65)
Study: 26426577
Drug: Clonidine 3 μg ml⁻¹
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 3 μg ml⁻¹
Study: 22944391
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg/2 mL)
Study: 22944391
Drug: Pheniramine hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pheniramine hydrogen maleate (45.5 mg/2 mL)
Study: 19586514
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no LHR treatment)
Study: 19586514
Drug: Side effects
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Side effects of LHR treatment
Study: 15344695
Drug: Budesonide, 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide, 4 mg/day
Study: 15344695
Drug: Intravenous prednisolone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous prednisolone, 120 mg/day
Study: 15344695
Drug: Oral prednisolone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone, 30 mg/day
Study: 7677241
Drug: Sedating antihistamines
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedating antihistamines (triprolidine, diphenhydramine, clemastine)
Study: 7677241
Drug: Nonsedating antihistamines
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsedating antihistamines (terfenadine, loratadine, cetirizine, acrivastine, mizolastine, ebastine)
Study: 2509528
Drug: recombinant tissue-type
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant tissue-type plasminogen activator (rt-PA) administration
Study: 25400062
Drug: Prasugrel plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel plus aspirin for 30 months
Study: 23873976
Drug: High-dose nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose nicotine patch therapy (42mg/day)
Study: 11104593
Drug: EPA-EE (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA-EE (6 g/d)
Study: 11104593
Drug: Placebo (OA-EE;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (OA-EE; 6 g/d)
Study: 28987023
Drug: Soluble hyaluronic
Normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Soluble hyaluronic acid (HA) microneedle patch plus adenosine wrinkle cream
Study: 28987023
Drug: Soluble hyaluronic
Normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Soluble hyaluronic acid (HA) microneedle patch alone
Study: 28987023
Drug: Adenosine wrinkle
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine wrinkle cream alone
Study: 22397651
Drug: Donepezil and
Normalized name: donepezil and memantine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil and memantine combination
Study: 20142596
Drug: Individualized prescribed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized prescribed total tumor dose (TTD) based on normal tissue dose constraints (mean lung dose, 19 Gy; maximal spinal cord dose, 54 Gy) up to a maximal TTD of 79.2 Gy in 1.8 Gy fractions twice daily
Study: 15821265
Drug: Antiviral drug
Normalized name: antiviral drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral drug prophylaxis
Study: 12349850
Drug: Insulin resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin resistance treatment with new drugs